



BETA DRUGS LIMITED

BDL/PKI/SEC/2021
25th October, 2021

To
The Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor
Plot no. C/I, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai — 400 051.

SYMBOL-BETA

Sub: Un-audited Standalone and Consolidated Financial Results for the half year ended on 30th September, 2021 under Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015.

Dear Sir/Madam,


Pursuant to the Regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015, we wish to inform that the Board of Directors of the company at their meeting held on Monday, 25th October, 2021 at 9:30 a.m. had considered and approved the Un-audited Standalone and Consolidated Financial Results for the half year ended on 30th September, 2021.

Pursuant to Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015, we are enclosing herewith the following:

1. Limited review Report on Standalone Financial Results for the half year ended 30th September, 2021.
2. Limited review Report on Consolidated Financial Results for the half year ended 30th September, 2021.
3. Un-Audited Standalone and Consolidated Financial Results for the half year ended 30th September, 2021.

This is for your information and appropriate dissemination.

Thanking You
Your's faithfully
For Beta Drugs Ltd.


Rajni Brar
Company Secretary



CIN No.: L24230HP2005PLC028969

Admin. Office : SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196



**KALRA RAI & ASSOCIATES
CHARTERED ACCOUNTANTS**

"A Peer Review Firm"

GSTIN:-04AAFFK0327H1ZT

LIMITED REVIEW REPORT

Independent Auditor's Review report on Interim Un-Audited Consolidated Financial Results for the half year ended on 30th September, 2021 pursuant to Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015 (as amended)

To,
The Board of Directors of
M/s Beta Drugs Limited
Village Nandpur, Lodhimajra Road
Baddi, Distt Solan
H.P. 174101

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **M/S BETA DRUGS LIMITED** ("the Parent") and its subsidiary ("the Parent" and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax for the half year ended 30th September, 2021 being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding half year ended 30/09/2021 as reported in these financial results have been approved by the Parent's Board of Directors, and have been subjected to review.

2. This Statement is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



4. The Statement includes the results of the following entities:

| Name of the Company | Relation |
|----------------------------|----------------------------------|
| Adley Formulations Pvt Ltd | Indian Subsidiary (wholly owned) |
| Adley Lab Limited | Indian Subsidiary (wholly owned) |

5. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited consolidated financial results, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. Our conclusion is not modified in respect of this matter.

7. The consolidated unaudited financial results includes the interim unaudited financial statements/ financial information/financial results of **M/s Adley Formulations Pvt Ltd (its subsidiary) & M/s Adley Lab Limited (its subsidiary)** which have not been reviewed/audited by their auditors, whose interim financial statements/ financial information/ financial results reflect total assets of Rs. 40,53,75,194.40 as at 30th September, 2021 and total revenue of Rs. 28,51,05,411.53 total net profit/(loss) after tax of Rs. 4,40,96,606.88 and total comprehensive income / loss of Rs. 4,40,96,606.88 for the half year ended 30th September, 2021 , respectively, and cash flows (net) of Rs. 44,91,087.63 for the period from 1st April 2021 to 30th September 2021 as considered in the consolidated unaudited financial results whose financial statement are not audited by us. This financial statement whose report have been furnished to us by the management and our opinion on the consolidated financial results in so far as it related to the amount and disclosure included in respect of this subsidiary is based solely on the reports of the management and procedure performed by us as stated in paragraph above.

Place: Chandigarh
Date: 25.10.2021

For KALRA RAI & ASSOCIATES
Chartered Accountants



(LAJPAT RAI KALRA)

Partner

M. No.: -087438

BETA DRUGS LIMITED

Village Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 173205

Phone : 01795-236196 E-Mail : betabaddi@gmail.com

CIN No. L24230HP2005PLC028969

Audited Consolidated Financial Results for the half year ended on 30th September' 2021

| Particulars | 6 Months Ended on 30/09/2021 (Unaudited) | 6 Months Ended on 31/03/2021 (Audited) | 6 Months Ended on 30/09/2020 (Audited) | Year Ended on 31/03/2021 (Audited) |
|---|---|---|---|---------------------------------------|
| I. Revenue From Operations | 88,09,55,012.49 | 64,74,16,349.47 | 51,38,02,787.72 | 1,16,12,19,137.19 |
| II. Other Income | 45,45,423.03 | 23,87,251.59 | 25,90,342.33 | 49,77,593.92 |
| III. Total Revenue (I+II) | 88,55,00,435.52 | 64,98,03,601.06 | 51,63,93,130.05 | 1,16,61,96,731.11 |
| IV. Expenses | | | | |
| a) Cost of Materials Consumed | 47,71,38,617.31 | 34,25,27,195.50 | 26,30,19,580.87 | 60,55,46,776.37 |
| b) Purchase of Stock-in-Trade | - | - | - | - |
| c) (Increase)/Decrease in Stock of Finished Goods/WIP | (1,03,45,608.40) | (2,07,31,060.43) | 29,86,258.75 | (1,77,44,801.68) |
| d) Other Manufacturing expenses | 8,73,95,272.18 | 7,59,57,203.99 | 5,80,55,994.86 | 13,40,13,198.85 |
| e) Employee benefit expenses | 6,93,88,227.90 | 6,06,69,098.10 | 4,81,56,259.00 | 10,88,25,357.10 |
| f) Finance Costs | 93,04,891.19 | 1,21,61,735.77 | 1,20,34,246.04 | 2,41,95,981.81 |
| g) Depreciation & amortisation expenses | 3,30,55,314.14 | 3,67,93,008.95 | 3,19,43,192.47 | 6,87,36,201.42 |
| h) Other expenses | 5,69,36,651.32 | 4,82,94,584.49 | 3,48,20,700.06 | 8,31,15,284.55 |
| Total Expenses | 72,28,73,365.64 | 55,56,71,766.37 | 45,10,16,232.05 | 1,00,66,87,998.42 |
| V. Profit before exceptional and extraordinary items and tax (III-IV) | 16,26,27,069.88 | 9,41,31,834.69 | 6,53,76,898.00 | 15,95,08,732.69 |
| VI. Exceptional Items | - | - | - | - |
| VII. Profit before extraordinary items and tax (V-VI) | 16,26,27,069.88 | 9,41,31,834.69 | 6,53,76,898.00 | 15,95,08,732.69 |
| VIII. Extraordinary Items | - | - | - | - |
| IX. Profit before tax (VII-VIII) | 16,26,27,069.88 | 9,41,31,834.69 | 6,53,76,898.00 | 15,95,08,732.69 |
| X. Tax Expenses | | | | |
| a) Current year tax | 4,69,49,226.37 | 3,18,69,751.24 | 1,52,06,089.18 | 4,70,75,840.42 |
| b) MAT credit/Deferred tax | (18,30,131.70) | (31,70,760.47) | (16,40,885.92) | (48,11,646.39) |
| XI. Profit (Loss) for the period from continuing operations (IX-X) | 11,75,07,975.21 | 6,54,32,843.92 | 5,18,11,694.75 | 11,72,44,538.66 |
| XII. Profit (Loss) from discounting operations | | | | |
| XIII. Tax expenses of discounting operations | | | | |
| XIV. Profit (Loss) from discounting operation (after tax) (XII-XIII) | | | | |
| XV. Net Profit/(Loss) for the period (XI+XIV) | 11,75,07,975.21 | 6,54,32,843.92 | 5,18,11,694.75 | 11,72,44,538.66 |
| XVI. Earning per share | | | | |
| a) Basic | 12.22 | 6.81 | 5.39 | 12.20 |
| b) Diluted | 12.22 | 6.81 | 5.39 | 12.20 |
| XVIII. Paid up equity share capital | 9,61,37,900.00 | 9,61,37,900.00 | 9,61,37,900.00 | 9,61,37,900.00 |
| Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year | 70,52,57,244.04 | 58,99,89,268.83 | 52,67,96,424.92 | 58,99,89,268.83 |

- The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held at 25th October 2021.
- The company is engaged in single business segment i.e. Pharmaceuticals.
- Figures are regrouped/rearranged, wherever considered necessary.

For KALRA RAI AND ASSOCIATES
Chartered Accountants
(FRN : 008859N)

LAJPAT RAI KALRA
PARTNER

Membership No. : 087438

UDIN : 21087438AAAAGL5456

Place : Chandigarh

Date : 25/10/2021

RAHUL BATRA
MANAGING DIRECTOR
DIN : 02229234

VARUN BATRA
DIRECTOR
DIN : 02148383

RAJNI BRAR
COMPANY SECRETARY
ACS24684

NIPUN ARORA
CFO

BETA DRUGS LIMITED

Village Nandpur, Lodhimaajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 173205

Phone : 01795-236196 E-Mail : betabaddi@gmail.com

CIN No. L24230HP2005PLC028969

Consolidated Statement of Assets & Liabilities for the half year ended on 30th September' 2021

| Particulars | As at 30th Sep' 2021 Amount in Rs. | As at 31st March' 2021 Amount in Rs. |
|---|---------------------------------------|---|
| 1. EQUITY AND LIABILITIES | | |
| (A) Shareholder's Funds | | |
| (a) Share Capital | 9,61,37,900.00 | 9,61,37,900.00 |
| (b) Reserves and Surplus | 70,52,57,244.04 | 58,99,89,268.83 |
| (c) Money received against share warrants | - | - |
| Sub-total-Shareholders' funds | 80,13,95,144.04 | 68,61,27,168.83 |
| (B) Non- Current Liabilities | | |
| (a) Long-term borrowings | 11,08,97,762.00 | 11,12,99,220.69 |
| (b) Deferred tax liabilities (Net) | - | - |
| (c) Other Long term liabilities | 2,33,62,840.00 | 2,26,67,275.00 |
| (d) Long term Provisions | 1,09,36,275.00 | 1,13,62,417.00 |
| Sub-total-Non- current liabilities | 14,51,96,877.00 | 14,53,28,912.69 |
| (C) Current Liabilities | | |
| (a) Short-term borrowings | 3,65,03,044.92 | 3,54,05,109.95 |
| (b) Trade Payable | 29,77,35,870.65 | 20,49,37,503.62 |
| (c) Other current liabilities | 8,22,34,375.03 | 8,90,64,824.16 |
| (d) Short-term provisions | 2,36,38,794.25 | 1,41,91,654.11 |
| Sub-total-current liabilities | 44,01,12,084.85 | 34,35,99,091.84 |
| TOTAL - EQUITY AND LIABILITIES | 1,38,67,04,105.90 | 1,17,50,55,173.37 |
| 2. ASSETS | | |
| (A) Non-current assets | | |
| (a) Fixed assets | | |
| (i) Property, Plant & Equipment | 36,30,90,521.24 | 36,45,47,461.00 |
| (ii) Intangible assets | 3,66,25,784.29 | 3,51,69,926.83 |
| (iii) Capital work-in-progress | 5,31,25,858.99 | 2,81,00,988.20 |
| (b) Non Current Investments | 77,89,905.49 | 77,89,905.49 |
| (c) Long Term Loan & Advance | 3,93,48,853.65 | 1,85,28,814.06 |
| (d) Other Non Current Assets | 1,75,13,181.32 | 3,35,29,279.69 |
| (e) Deferred tax Assets | 83,06,445.77 | 64,76,314.08 |
| Sub-total-Non-current assets | 52,58,00,550.76 | 49,41,42,689.35 |
| (B) Current Assets | | |
| (a) Inventories | 19,36,24,926.84 | 16,04,25,446.92 |
| (b) Trade receivable | 44,02,73,507.83 | 33,87,64,370.00 |
| (c) Cash and bank balance | 13,81,78,906.84 | 10,42,47,300.46 |
| (d) Short-term loan and advances | 3,45,11,054.48 | 2,42,40,991.86 |
| (e) Other current assets | 5,43,15,159.15 | 5,32,34,374.78 |
| Sub-total-current assets | 86,09,03,555.14 | 68,09,12,484.02 |
| TOTAL - ASSETS | 1,38,67,04,105.90 | 1,17,50,55,173.37 |

- The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held at 25th October 2021.
- The company is engaged in single business segment i.e. Pharmaceuticals.
- Figures are regrouped/rearranged, wherever considered necessary.

For KALRA RAI AND ASSOCIATES
Chartered Accountants
(FRN : 008859N)

LAJPAT RAI KALRA
PARTNER
Membership No. : 087438
UDIN: 21087428AAAGL5456
Place : Chandigarh
Date : 25/10/2021

For and on Behalf of Board of Directors

RAHUL BATRA
DIRECTOR
DIN : 02229234

VARUN BATRA
DIRECTOR
DIN: 02148383

BETA DRUGS LIMITED

Village Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 173205

Phone : 01795-236196 E-Mail : betabaddi@gmail.com

CIN No. L24230HP2005PLC028969

Consolidated Cashflow Statement for the year ended on 30th September' 2021

| Particulars | As at 30 Sep' 2021 | As at 31 March' 2021 |
|--|-------------------------|-------------------------|
| | Amount in Rs. | Amount in Rs. |
| A CASHFLOW FROM OPERATING ACTIVITIES | | |
| Net Profit before tax and extraordinary items (as per Statement of Profit & Loss) | 16,26,27,069.88 | 15,95,08,732.69 |
| Adjustments for non Cash/Non trade items: | | |
| Depreciation & Amortization Expenses | 3,30,55,314.14 | 6,87,36,201.42 |
| Finance Cost | 93,04,891.19 | 2,41,95,981.81 |
| Interest received | (19,28,153.00) | (33,44,427.55) |
| Other inflows/(outflows) of cash | (2,41,52,129.86) | (2,41,72,864.14) |
| Operating profits before Working Capital Changes | 17,89,06,992.35 | 22,49,23,624.23 |
| Adjusted For: | | |
| (Increase)/Decrease in trade receivables | (10,15,09,137.83) | (1,94,95,819.90) |
| Increase/(Decrease) in trade payables | 9,27,98,367.03 | 6,00,47,083.92 |
| (Increase)/Decrease in inventories | (3,31,99,479.92) | (3,69,60,372.54) |
| Increase/(Decrease) in other current liabilities | (68,30,449.13) | (2,44,08,142.77) |
| (Increase)/Decrease in short term loans and advances | (1,02,70,062.62) | (96,85,002.61) |
| (Increase)/Decrease in other current assets | (10,80,784.37) | (84,22,955.74) |
| Net Changes in working capital | (6,00,91,546.84) | (3,89,25,209.64) |
| Net cashflow from Operating Activities (A) | 11,88,15,445.51 | 18,59,98,414.59 |
| B CASHFLOW FROM INVESTING ACTIVITIES | | |
| Purchase of tangible/intangible assets | (5,80,79,102.64) | (5,75,55,411.97) |
| Interest received | 19,28,153.00 | 33,44,427.55 |
| Cash used for Non Current Investments | - | (42,69,312.87) |
| Cash used for Long Term Loans/Advances | (2,08,20,039.59) | - |
| Net cash used in Investing Activities (B) | (7,69,70,989.23) | (5,84,80,297.29) |
| C CASHFLOW FROM FINANCING ACTIVITIES | | |
| Finance Cost | (93,04,891.19) | (2,41,95,981.81) |
| Increase in/(Repayment) of Short term Borrowings | 10,97,934.98 | (6,10,79,426.08) |
| Increase in/(Repayment) of Long term Borrowings | 2,94,106.31 | 81,34,994.09 |
| Increase/ (Decrease) in share capital | - | - |
| Increase/ (Decrease) in share premium | - | - |
| Other Inflows/ (Outflows) of cash | - | - |
| Net cash used in Financing Activities (C) | (79,12,849.90) | (7,71,40,413.80) |
| D Net Increase/(Decrease) in cash & cash equivalents (A+B+C) | 3,39,31,606.38 | 5,03,77,703.50 |
| E Cash & Cash equivalents at beginning of period | 10,42,47,300.46 | 5,38,69,596.96 |
| F Cash & Cash equivalents at end of period | 13,81,78,906.84 | 10,42,47,300.46 |
| G Net Increase/(Decrease) in cash & cash equivalents (F-E) | 3,39,31,606.38 | 5,03,77,703.50 |

- The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held at 25th October 2021.
- The company is engaged in single business segment i.e. Pharmaceuticals.
- Figures are regrouped/rearranged, wherever considered necessary.

For KALRA RAI AND ASSOCIATES

Chartered Accountants

(FRN : 008859N)

Accountants
FRN 008859N

LAJPAT RAI KALRA

PARTNER

Membership No. : 087438

Place : Chandigarh

Date : 25/10/2021

For and on Behalf of Board of Directors



RAHUL BATRA

DIRECTOR

DIN : 02229234



VARUN BATRA

DIRECTOR

DIN: 02148383





**KALRA RAI & ASSOCIATES
CHARTERED ACCOUNTANTS**

"A Peer Review Firm"

GSTIN:-04AAFFK0327H1ZT

LIMITED REVIEW REPORT

Independent Auditor's Review report on Interim Un-Audited Standalone Financial Results for the half year ended on 30th September, 2021 pursuant to Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015 (as amended)

To,
The Board of Directors of
M/s Beta Drugs Limited
Village Nandpur, Lodhimajra Road
Baddi, Distt Solan
H.P. 174101

We have reviewed the accompanying statement of unaudited standalone financial results of **M/s Beta drugs Limited ("the company")** for the half year ended **30th September, 2021**. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Chandigarh
Date: 25.10.2021

For KALRA RAI & ASSOCIATES
Chartered Accountants



(LAJPAT RAI KALRA)
Partner
M. No.:-087438

BETA DRUGS LIMITED
Village Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 173205
Phone : 01795-236196 E-Mail : betabaddi@gmail.com
CIN No. L24230HP2005PLC028969
Audited Standalone Financial Results for the half year ended on 30th September' 2021

| Particulars | 6 Months Ended on 30/09/2021 (Unaudited) | 6 Months Ended on 31/03/2021 (Audited) | 6 Months Ended on 30/09/2020 (Audited) | Year Ended on 31/03/2021 (Audited) |
|--|---|---|---|---------------------------------------|
| I. Revenue From Operations | 59,52,94,752.99 | 44,63,57,677.41 | 34,82,06,441.28 | 79,45,64,118.69 |
| II. Other Income | 51,00,271.00 | 34,12,498.10 | 26,99,889.26 | 61,12,387.36 |
| III. Total Revenue (I+II) | 60,03,95,023.99 | 44,97,70,175.51 | 35,09,06,330.54 | 80,06,76,506.05 |
| IV. Expenses | | | | |
| a) Cost of Materials Consumed | 33,72,27,942.29 | 25,66,76,258.03 | 19,16,38,409.01 | 44,83,14,667.04 |
| b) Purchase of Stock-in-Trade | - | - | - | - |
| c) (Increase)/Decrease in Stock of Finished Goods/WIP | (21,37,266.33) | (1,34,58,137.09) | (3,71,178.34) | (1,38,29,315.43) |
| d) Other Manufacturing expenses | 6,07,40,626.09 | 5,24,18,507.65 | 4,16,30,642.86 | 9,40,49,150.51 |
| e) Employee benefit expenses | 3,60,13,257.90 | 3,45,34,814.10 | 2,60,27,899.00 | 6,05,62,713.10 |
| f) Finance Costs | 21,14,518.93 | 37,90,989.31 | 39,36,039.19 | 77,27,028.50 |
| g) Depreciation & amortisation expenses | 2,48,55,385.35 | 2,76,91,728.96 | 2,49,82,275.05 | 5,26,74,004.01 |
| h) Other expenses | 3,78,80,964.24 | 2,97,54,825.00 | 2,26,12,148.56 | 5,23,66,973.56 |
| Total Expenses | 49,66,95,428.46 | 39,14,08,985.96 | 31,04,56,235.32 | 70,18,65,221.29 |
| V. Profit before exceptional and extraordinary items and tax (III-IV) | 10,36,99,595.53 | 5,83,61,189.55 | 4,04,50,095.22 | 9,88,11,284.76 |
| VI. Exceptional Items | - | - | - | - |
| VII. Profit before extraordinary items and tax (V-VI) | 10,36,99,595.53 | 5,83,61,189.55 | 4,04,50,095.22 | 9,88,11,284.76 |
| VIII. Extraordinary Items | - | - | - | - |
| IX. Profit before tax (VII-VIII) | 10,36,99,595.53 | 5,83,61,189.55 | 4,04,50,095.22 | 9,88,11,284.76 |
| X. Tax Expenses | | | | |
| a) Current year tax | 3,18,94,491.73 | 2,17,86,690.63 | 1,12,36,759.03 | 3,30,23,449.66 |
| b) MAT credit/Deferred tax | (16,06,264.53) | (25,84,659.95) | (14,05,260.51) | (39,89,920.45) |
| XI. Profit (Loss) for the period from continuing operations (IX-X) | 7,34,11,368.33 | 3,91,59,158.87 | 3,06,18,596.69 | 6,97,77,755.55 |
| XII. Profit (Loss) from discounting operations | | | | |
| XIII. Tax expenses of discounting operations | | | | |
| XIV. Profit (Loss) from discounting operation (after tax) (XII-XIII) | - | - | - | - |
| XV. Net Profit/(Loss) for the period (XI+XIV) | 7,34,11,368.33 | 3,91,59,158.87 | 3,06,18,596.69 | 6,97,77,755.55 |
| XVI. Earning per share | | | | |
| a) Basic | 7.64 | 4.07 | 3.18 | 7.26 |
| b) Diluted | 7.64 | 4.07 | 3.18 | 7.26 |
| XVIII. Paid up equity share capital | 9,61,37,900.00 | 9,61,37,900.00 | 9,61,37,900.00 | 9,61,37,900.00 |
| Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year | 61,14,42,009.79 | 53,80,30,641.46 | 49,88,71,482.60 | 53,80,30,641.46 |

- The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held at 25th October 2021.
- The company is engaged in single business segment i.e. Pharmaceuticals.
- Figures are regrouped/rearranged, wherever considered necessary.

For KALRA RAI AND ASSOCIATES
Chartered Accountants
(FRN : 008859N)

LAJPAT RAI KALRA
PARTNER
Membership No. : 087438
UDIN: 21087438AAAAGM3690
Place : Chandigarh
Date : 25/10/2021

RAHUL BATRA
MANAGING DIRECTOR
DIN : 02229234

VARUN BATRA
DIRECTOR
DIN: 02148383

RAJNI BRAR
COMPANY SECRETARY
ACS24684

For and on Behalf of Board of Directors

NIPUN ARORA
CFO

BETA DRUGS LIMITED

Village Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 173205

Phone : 01795-236196 E-Mail : betabaddi@gmail.com

CIN No. L24230HP2005PLC028969

Standalone Statement of Assets & Liabilities for the half year ended on 30th September' 2021

| Particulars | As at 30th Sep' 2021 Amount in Rs. | As at 31st March' 2021 Amount in Rs. |
|---|---------------------------------------|---|
| 1. EQUITY AND LIABILITIES | | |
| (A) Shareholder's Funds | | |
| (a) Share Capital | 9,61,37,900.00 | 9,61,37,900.00 |
| (b) Reserves and Surplus | 61,14,42,009.79 | 53,80,30,641.46 |
| (c) Money received against share warrants | | |
| Sub-total-Shareholders' funds | 70,75,79,909.79 | 63,41,68,541.46 |
| (B) Non- Current Liabilities | | |
| (a) Long-term borrowings | 2,66,64,166.00 | 3,38,63,312.69 |
| (b) Deferred tax liabilities (Net) | - | - |
| (c) Other Long term liabilities | 30,48,000.00 | 26,49,000.00 |
| (d) Long term Provisions | 75,73,390.00 | 79,99,532.00 |
| Sub-total-Non- current liabilities | 3,72,85,556.00 | 4,45,11,844.69 |
| (C) Current Liabilities | | |
| (a) Short-term borrowings | - | 50,08,697.47 |
| (b) Trade Payable | 18,36,20,696.78 | 13,24,39,138.46 |
| (c) Other current liabilities | 4,01,06,755.88 | 4,04,48,061.88 |
| (d) Short-term provisions | 1,27,35,993.04 | 57,45,458.38 |
| Sub-total-current liabilities | 23,64,63,445.70 | 18,36,41,356.19 |
| TOTAL - EQUITY AND LIABILITIES | 98,13,28,911.49 | 86,23,21,742.35 |
| 2. ASSETS | | |
| (A) Non-current assets | | |
| (a) Fixed assets | | |
| (i) Property, Plant & Equipment | 27,14,12,779.02 | 27,44,63,684.91 |
| (ii) Intangible assets | 52,61,054.79 | 56,43,868.43 |
| (iii) Capital work-in-progress | 3,08,55,606.85 | 1,90,28,682.41 |
| (b) Non Current Investments | 6,54,29,905.49 | 6,54,29,905.49 |
| (c) Long Term Loan & Advance | 3,90,31,251.59 | 3,35,04,481.00 |
| (d) Other Non Current Assets | 1,07,93,181.29 | 2,45,69,279.69 |
| (e) Deferred tax Assets | 52,70,536.12 | 36,64,271.59 |
| Sub-total-Non-current assets | 42,80,54,315.15 | 42,63,04,173.52 |
| (B) Current Assets | | |
| (a) Inventories | 8,41,16,170.97 | 7,69,50,318.81 |
| (b) Trade receivable | 29,26,56,612.90 | 20,80,80,401.12 |
| (c) Cash and bank balance | 12,10,84,246.82 | 8,26,61,552.81 |
| (d) Short-term loan and advances | 1,37,41,392.63 | 1,99,12,178.91 |
| (e) Other current assets | 4,16,76,173.02 | 4,84,13,117.18 |
| Sub-total-current assets | 55,32,74,596.34 | 43,60,17,568.83 |
| TOTAL - ASSETS | 98,13,28,911.49 | 86,23,21,742.35 |

- The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held at 25th October 2021.
- The company is engaged in single business segment i.e. Pharmaceuticals.
- Figures are regrouped/rearranged, wherever considered necessary.

For KALRA RAI AND ASSOCIATES

Chartered Accountants

(FRN : 008859N)

FRN 008859N

LAJPAT RAI KALRA

PARTNER

Membership No. : 087438

UDIN: 21087438AAAAGM3690

Place : Chandigarh

Date : 25/10/2021

For and on Behalf of Board of Directors

RAHUL BATRA
MANAGING DIRECTOR
DIN : 02229234

VARUN BATRA
DIRECTOR
DIN: 02148383

BETA DRUGS LIMITED

Village Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 173205

Phone : 01795-236196 E-Mail : betabaddi@gmail.com

CIN No. L24230HP2005PLC028969

Standalone Cashflow Statement for the half year ended on 30th September' 2021

| Particulars | As at 30 Sep' 2021 | As at 31 March' 2021 |
|---|-------------------------|-------------------------|
| | Amount in Rs. | Amount in Rs. |
| A CASHFLOW FROM OPERATING ACTIVITIES | | |
| Net Profit before tax and extraordinary items (as per Statement of Profit & Loss) | 10,36,99,595.53 | 9,88,11,284.76 |
| Adjustments for non Cash/Non trade items: | | |
| Depreciation & Amortization Expenses | 2,48,55,385.35 | 5,26,74,004.01 |
| Finance Cost | 21,14,518.93 | 77,27,028.50 |
| Interest received | (29,97,601.00) | (56,99,508.36) |
| Other inflows/(outflows) of cash | (1,15,54,000.67) | (1,47,34,377.53) |
| Operating profits before Working Capital Changes | 11,61,17,898.13 | 13,87,78,431.39 |
| Adjusted For: | | |
| (Increase)/Decrease in trade receivables | (8,45,76,211.78) | 10,07,137.99 |
| Increase/(Decrease) in trade payables | 5,11,81,558.32 | 3,97,70,385.12 |
| (Increase)/Decrease in inventories | (71,65,852.16) | (1,59,57,583.44) |
| Increase/(Decrease) in other current liabilities | (3,41,306.00) | (3,58,93,124.78) |
| (Increase)/Decrease in short term loans and advances | 61,70,786.28 | (12,82,135.30) |
| (Increase)/Decrease in other current assets | 67,36,944.16 | (1,04,35,192.74) |
| Net Changes in working capital | (2,79,94,081.18) | (2,27,90,513.15) |
| Net cashflow from Operating Activities (A) | 8,81,23,816.95 | 11,59,87,918.24 |
| B CASHFLOW FROM INVESTING ACTIVITIES | | |
| Purchase of tangible/intangible assets | (3,32,48,590.26) | (3,43,42,726.02) |
| Interest received | 29,97,601.00 | 56,99,508.36 |
| Cash used for Non Current Investments | - | (42,69,312.87) |
| Cash used for Long Term Loans/Advances | (55,26,770.59) | 13,76,818.00 |
| Net cash used in Investing Activities (B) | (3,57,77,759.85) | (3,15,35,712.53) |
| C CASHFLOW FROM FINANCING ACTIVITIES | | |
| Finance Cost | (21,14,518.93) | (77,27,028.50) |
| Increase in/(Repayment) of Short term Borrowings | (50,08,697.47) | (3,46,83,254.35) |
| Increase in/(Repayment) of Long term Borrowings | (68,00,146.69) | (9,93,601.68) |
| Increase/ (Decrease) in share capital | - | - |
| Increase/ (Decrease) in share premium | - | - |
| Other Inflows/ (Outflows) of cash | - | - |
| Net cash used in Financing Activities (C) | (1,39,23,363.09) | (4,34,03,884.53) |
| D Net Increase/(Decrease) in cash & cash equivalents (A+B+C) | 3,84,22,694.01 | 4,10,48,321.18 |
| E Cash & Cash equivalents at beginning of period | 8,26,61,552.81 | 4,16,13,231.63 |
| F Cash & Cash equivalents at end of period | 12,10,84,246.82 | 8,26,61,552.81 |
| G Net Increase/(Decrease) in cash & cash equivalents (F-E) | 3,84,22,694.01 | 4,10,48,321.18 |

- The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held at 25th October 2021.
- The company is engaged in single business segment i.e. Pharmaceuticals.
- Figures are regrouped/rearranged, wherever considered necessary.

For KALRA RAI AND ASSOCIATES

Chartered Accountants

(FRN : 008859N)

LAJPAT RAI KALRA

PARTNER

Membership No. : 087438

Place : Chandigarh

Date : 25/10/2021

For and on Behalf of Board of Directors

RAHUL BATRA
MANAGING DIRECTOR
DIN : 02229234

VARUN BATRA
DIRECTOR
DIN: 02148383



BETA DRUGS LIMITED

MANAGEMENT DISCUSSION & ANALYSIS

Beta consolidated revenues for the first six months of FY22 grew by 71% to Rs 88.1 crores from Rs 51.4 crores compared with the same period a year ago. This growth was mainly driven by 140% increase in sale of branded oncology products across all geographies. The company has continued to expand its presence across corporate hospitals in India and has also marked its presence in Tier II & III cities. Its CMO business grew by 66%.

Consolidated EBITDA grew by 87.5% to Rs 20.5 crores from 11 crores compared with the year ago period. EBITDA margin stood at 23.27% expanding by 200 basis points. Margin expansion was due to increased sale of high margin branded products as well leveraging technology to drive efficiencies.

Net profit too increased by 127% to Rs 11.75 crores from Rs 5.18 crores compared with the same period a year ago.

The company was able to reduce its debtors days to 90 days compared with 106 days while inventory days stood at 40 days compared with 50 days in the year ago period. This led to shortening of working capital cycle which stood at 69 days as against 92 days.

GUIDANCE FOR SECOND HALF

Management expects to better its first half's financial performance. While its own brand sales and exports will continue to grow at a healthy clip, it expects exports and API to give further boost to its numbers in the second half.

The company has recently added senior management talent to its exports team and expects it to be a major growth driver going forward. Its API plant recently received its WHO- GMP approval, increased its manufacturing capacity and is working towards filing its DMF by mid of next year in the European market which will help the company to enter regulated markets thus positively impacting the company's financial performance going forward.



CIN No.: L24230HP2005PLC028969

Admin. Office : SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

Website :- www.betadrugslimited.com

E-Mail :- info@betadrugslimited.com



BETA DRUGS LIMITED

BDL/PKL/SEC/2021

25th October, 2021

To
The Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor
Plot no. C/I, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai — 400 051.

Sub: Certificate as per regulation 33(2)(a) of SEBI(LODR) Regulations, 2015

Dear Sir/Madam

We the undersigned, in our respective capacities as Managing Director and Chief Financial Officer of Beta Drugs Limited, certify that the Interim Standalone and Consolidated Un-Audited Financial results for the half year ended 30th September, 2021 do not contain any false or misleading statement or figures and do not omit any material fact which may make the statements or figures contained therein misleading.

Thanking You
Your's faithfully

For Beta Drugs Limited


Mr Rahul Batra
Managing Director
DIN: 02229234


Mr Nipun Arora,
Chief Financial Officer

CIN No.: L24230HP2005PLC028969

Admin. Office : SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

Website :- www.betadrugslimited.com

E-Mail :- info@betadrugslimited.com